TY - JOUR T1 - Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens JF - J Int AIDS Soc Y1 - 2014 A1 - Eron, J.J. A1 - Lalezari, J. A1 - Slim, J. A1 - Gathe, J. A1 - P J Ruane A1 - Wang, C. A1 - Elion, R. A1 - Blick, G. A1 - Khatri, A. A1 - Hu, Y.B. A1 - Gibbons, K. A1 - Fredrick, L. A1 - Co, M. A1 - D'Amico, R. A1 - Da Silva-Tillmann, B. A1 - Trinh, R. A1 - M S Sulkowski KW - abnormalities KW - Affect KW - Antiretroviral KW - Antiretroviral Therapy KW - Arm KW - atazanavir KW - Baltimore KW - Bilirubin KW - Chicago KW - Clinical Medicine KW - co-infected KW - co-infection KW - coinfection KW - Disease KW - Genotype KW - HCV KW - Health KW - hepatitis KW - Hiv KW - Hiv-1 KW - Hyperbilirubinemia KW - Infectious Disease Medicine KW - Jaundice KW - Laboratories KW - Los Angeles KW - Medicine KW - methods KW - North Carolina KW - Patients KW - pharmacokinetic KW - pharmacokinetics KW - Plasma KW - raltegravir KW - Research KW - Ribavirin KW - ritonavir KW - Rna KW - Safety KW - San Francisco KW - Statistics KW - SVR KW - therapy KW - treatment KW - treatment-naive KW - Universities KW - Washington VL - 17 SP - 19500 IS - 4 Suppl 3 N1 - PMC4224905 ER -